Leadership Overview
AxoGen has 4 executives leading key functions including strategy, finance, marketing, and medical affairs.
Driven by innovation in surgical solutions, AxoGen is dedicated to advancing the treatment of peripheral nerve injuries, enhancing patient outcomes through specialized medical devices and diagnostic tools.
Driven by innovation in surgical solutions, AxoGen is dedicated to advancing the treatment of peripheral nerve injuries, enhancing patient outcomes through specialized medical devices and diagnostic tools.
Leadership Roles at AxoGen
Karen Zaderej - President, Chief Executive Officer & Chairman
Karen Zaderej, the President, Chief Executive Officer & Chairman at AxoGen, directs the company's overarching strategy and corporate governance. Overseeing all business operations, Zaderej ensures the successful development and market penetration of AxoGen's surgical solutions for peripheral nerve injuries, including nerve grafts, connectors, and protectors. This leadership role involves guiding the company's expansion across North America, Europe, and international markets, driving the adoption of innovative products like the Avance Nerve Graft and AxoGuard Nerve Protector. By fostering strategic partnerships and maintaining a clear vision for nerve repair and regeneration, Karen Zaderej significantly impacts the company's growth and its ability to serve surgeons and patients globally. The Chairman's responsibilities include setting long-term objectives and ensuring alignment with shareholder value.
Lindsey Peterson - Chief Financial Officer
Lindsey Peterson, the Chief Financial Officer at AxoGen, manages all financial operations and fiscal strategy. Overseeing budgeting, forecasting, and financial reporting, Peterson ensures the company's financial health and supports its growth initiatives in the medical device sector. This critical role involves managing capital allocation for research and development of surgical solutions for peripheral nerve injuries, including nerve grafts and protectors. By optimizing financial performance and securing necessary funding, Lindsey Peterson directly contributes to AxoGen's ability to distribute its innovative products, such as the Avance Nerve Graft and AcroVal neurosensory testing system, to hospitals and surgery centers across its global distribution network. The Chief Financial Officer's oversight extends to investor relations and ensuring compliance with financial regulations.
Jens Kemp - Chief Marketing Officer
Jens Kemp, the Chief Marketing Officer at AxoGen, spearheads the strategic marketing and commercialization efforts for the company's peripheral nerve repair solutions. Overseeing all marketing campaigns and product positioning, Kemp drives market awareness and adoption of AxoGen's comprehensive portfolio, including nerve grafts, connectors, and protectors. This leadership function involves developing go-to-market strategies for innovative products like the Avance Nerve Graft and AxoGuard Nerve Protector, targeting surgeons and medical facilities across North America, Europe, and other international markets. By translating the clinical benefits of AxoGen's offerings into compelling market narratives, Jens Kemp ensures the company effectively reaches its target audience and expands its reach in the specialized field of nerve regeneration. The Chief Marketing Officer's focus includes digital marketing, trade shows, and physician education.
Ivica Ducic - Chief Medical Officer
Ivica Ducic, the Chief Medical Officer at AxoGen, provides critical clinical leadership and medical expertise to guide the development and application of the company's surgical solutions for peripheral nerve injuries. Overseeing clinical strategy and medical affairs, Ducic ensures that AxoGen's products, such as nerve grafts, connectors, and protectors, meet the highest standards of patient care and clinical efficacy. This role involves collaborating with surgeons and medical professionals to gather insights that inform product innovation, including advancements in nerve repair and regeneration technologies like the Avance Nerve Graft and AxoGuard Nerve Protector. By championing the clinical value of AxoGen's offerings, Ivica Ducic supports the company's mission to improve outcomes for patients with nerve damage across its global distribution channels. The Chief Medical Officer also guides clinical trial design and medical education initiatives.
Explore Leadership Teams in Manufacturing
Solventum will embody its mission of enabling better, smarter, safer healthcare to improve lives. With a dedicated focus on solving big healthcare challenges, the independent healthcare company will push the boundaries of health, material and datascience to improve outcomes across the healthcare ecosystem. Its diverse product portfolio spans across the healthcare industry from medical solutions and oral care to health information systems and separation and purification sciences.
Company Leadership
LY
GG
JX
Advita Ortho, headquartered in Gainesville, Florida, is a global medical device company dedicated to advancing patient lives through innovative orthopedic solutions. Officially launched in November 2025, the company delivers high-quality orthopedic implants and a comprehensive suite of integrated surgical technologies powered by data, artificial intelligence, and machine learning. Advita Ortho owns and distributes established product lines including the Equinoxe Shoulder, Vantage Ankle, Alteon Hip, Truliant Knee, Newton balancing technology, and GPS navigation systems, among others. The company's portfolio creates an ecosystem designed to enhance surgical decision-making in the operating room while driving efficiency for healthcare systems. Led by industry veterans and backed by investment firms including Strategic Value Partners, Stellex Capital Management, and Greywolf Capital Management, Advita Ortho positions itself as a trusted partner to orthopedic surgeons worldwide, providing tools and technologies designed to improve patient outcomes and quality of life.
Company Leadership
Headquartered in Marlborough, Massachusetts, and formerly part of GE Healthcare Life Sciences, Cytiva is a global provider of medical application technologies and services that advance and accelerate the development of therapeutics.
Company Leadership SO
RM
AL
SE
As per the "buy and build" strategy, the next acquisition was Legacy Medical (July 2018), followed by Haemotec (Nov 2019) and LTE Medical Supplies (Feb 2019). In April 2019, the company started an Ophthalmology business (EyeCare) and have expanded the company's product range and agencies in the existing verticals. The second half of 2019 saw further acquisitions with Paragmed in November and Jumla Medical Supplies and Stratmed joining the group in December. The company is a scaled and diversified group of specialised medical service providers committed to bringing new, first-rate technologies to a wide spectrum of medical practitioners. The company provides the latest devices, software, processes and procedures that facilitate high care and quality treatment for all patients. The company's clients and partners continually receive extensive training and comprehensive technical support as the company strives towards better products, better services and more personalised customer experiences. Depiction of Vertice MedTech
Company Leadership HP
GS
BM
EM
Frequently Asked Questions Regarding AxoGen Top Executives and Leadership Team
